Cancer: a family at risk
K Woźniak, D Iżycki - Menopause Review/Przegląd Menopauzalny, 2014 - termedia.pl
The diagnosis of cancer is a family experience that changes the lives of all its members,
bringing an immense amount of stress and many challenging situations. The daily routine, …
bringing an immense amount of stress and many challenging situations. The daily routine, …
[HTML][HTML] Inclusion biogenesis, methods of isolation and clinical application of human cellular exosomes
…, R Sibiak, H Piotrowska-Kempisty, D Iżycki… - Journal of clinical …, 2020 - mdpi.com
Exosomes are a heterogenous subpopulation of extracellular vesicles 30–150 nm in range
and of endosome-derived origin. We explored the exosome formation through different …
and of endosome-derived origin. We explored the exosome formation through different …
Consequences of gynecological cancer in patients and their partners from the sexual and psychological perspective
D Iżycki, K Woźniak, N Iżycka - Menopause Review/Przegląd …, 2016 - termedia.pl
The diagnosis of gynecological cancer and the following consequences of the treatment
radically change the lives of cancer patients and their partners. Women experience negative …
radically change the lives of cancer patients and their partners. Women experience negative …
[HTML][HTML] Human umbilical vein endothelial cells (HUVECs) co-culture with osteogenic cells: from molecular communication to engineering prevascularised bone grafts
…, P Antosik, D Bukowska, M Bruska, D Iżycki… - Journal of clinical …, 2019 - mdpi.com
The repair of bone defects caused by trauma, infection or tumor resection is a major clinical
orthopedic challenge. The application of bone grafts in orthopedic procedures is associated …
orthopedic challenge. The application of bone grafts in orthopedic procedures is associated …
[HTML][HTML] CRISPR/Cas9 in cancer immunotherapy: animal models and human clinical trials
…, I Kocherova, J Petitte, P Mozdziak, JA Shibli, D Iżycki… - Genes, 2020 - mdpi.com
Even though chemotherapy and immunotherapy emerged to limit continual and unregulated
proliferation of cancer cells, currently available therapeutic agents are associated with high …
proliferation of cancer cells, currently available therapeutic agents are associated with high …
Chemotherapy-induced peripheral neuropathy—diagnosis, evolution and treatment
…, M Kaźmierczak, T Piorunek, N Iżycka… - Ginekologia …, 2016 - journals.viamedica.pl
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent neurologic
complications experienced by patients receiving antineoplastic drugs. Involvement of the …
complications experienced by patients receiving antineoplastic drugs. Involvement of the …
[HTML][HTML] Immunotherapy in ovarian cancer
…, R Czepczyński, MP Zaborowski, D Iżycki - Archivum Immunologiae …, 2022 - Springer
Despite advances in surgery and chemotherapy, ovarian cancer remains one of the most
lethal malignancies. Hence, the implementation of novel treatment approaches is required to …
lethal malignancies. Hence, the implementation of novel treatment approaches is required to …
[HTML][HTML] [99mTc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes
…, P Kanellopoulos, B Janota, B Bromińska, D Iżycki… - Cancers, 2021 - mdpi.com
Simple Summary Radiolabeled gastrin-releasing peptide receptor (GRPR)-antagonists have
been proposed for diagnostic imaging and radionuclide therapy—theranostics—of human …
been proposed for diagnostic imaging and radionuclide therapy—theranostics—of human …
[HTML][HTML] Biological response of adrenal carcinoma and melanoma cells to mitotane treatment
…, K Jopek, A Żok, D Iżycki… - Oncology …, 2022 - spandidos-publications.com
A previous case report described an adrenal incidentaloma initially misdiagnosed as
adrenocortical carcinoma (ACC), which was treated with mitotane. The final diagnosis was …
adrenocortical carcinoma (ACC), which was treated with mitotane. The final diagnosis was …
[HTML][HTML] New and old genes associated with primary and established responses to paclitaxel treatment in ovarian cancer cell lines
…, A Klejewski, M Brazert, D Kaźmierczak, D Iżycki… - Molecules, 2018 - mdpi.com
Development of drug resistance is the main reason for low chemotherapy effectiveness in
treating ovarian cancer. Paclitaxel (PAC) is a chemotherapeutic drug used in the treatment of …
treating ovarian cancer. Paclitaxel (PAC) is a chemotherapeutic drug used in the treatment of …